SREBF1 and metabolic dysfunction-associated steatotic liver disease: Especially observed at high levels in MASLD, fetuin-B aggravates insulin resistance by blocking AMPK and activating the LXR-SREBP1c axis, hence fostering hepatic lipogenesis [80,81].